Weeks 9 to 12: the second step and the first real numbers

By week 9 the routine is set: same day, rotated site, a log. The third label step is 1 mg for Wegovy and 7.5 mg for Zepbound (section 2.1). This is also where the first-time reader usually stops needing a week-by-week page and starts needing the long-form guides; this page hands over.

What usually settles

For most people the acute nausea has become predictable by now: a day or two after a step up, less after a held dose. The label statement that gastrointestinal reactions decrease over time is about this stretch and beyond. Appetite is lower and stable. Injection-day anxiety is gone.

What often does not

• Constipation tends to persist where nausea passes. Fluids, fibre, movement; and mention it at the check-in.
• Fatigue is in both label tables (Wegovy 11% vs 5%; Zepbound 5 to 7% vs 3%), and in practice it often tracks under-eating. Check protein and total intake before assuming it is the drug.
• Reflux and burping are in both tables and are more noticeable at higher doses.
• Hair loss appears in the Zepbound table (4 to 5% vs 1%) and is generally associated with rapid weight loss rather than the molecule; it is a fair question for a prescriber, not an emergency.

Follow-up and labs

Many prescribers set a fuller review around three months: weight, blood pressure, heart rate (the labels report a mean resting heart rate increase), a symptom review, and repeat labs if a baseline was abnormal or if you have diabetes and your other medicines may need adjusting. The Lab Guide explains what each test is for and has a tracker for the numbers. If you take insulin or a sulfonylurea, the hypoglycemia warning in section 5.4 is the reason a prescriber may already have lowered those doses; report any low-sugar episodes.

The first numbers that mean something

Week 12 is the first point where the trial figures start to say something about you, and even here they say it cautiously. In STEP 1 the semaglutide group's curve at week 12 sat well below placebo, but participants had not yet reached 2.4 mg (that came at week 17) and the group went on losing weight for most of the following year; the 14.9% figure is from week 68 (PubMed 33567185). In SURMOUNT-1, participants at week 12 were on 7.5 mg at most, still escalating; the 15.0 to 20.9% figures are from week 72 (PubMed 35658024). Your week-12 number is one point on a line whose slope matters more than its level. When weight change starts shows the curves and what the responder rates were at the end.

If you want your own weight put against the published averages, the weight-loss projection tool does that, labelled as population averages, which is what they are.

The word "plateau"

A four-week flat patch at week 10 is not a plateau in any sense the trials measured. Weight swings with fluid, sodium, bowel habit, menstrual cycle and the scale itself. The people in the trials kept escalating through this window and kept losing weight on average for a year or more. Do not change your dose, skip a step, or add a second product on your own. The network's Weight Loss on GLP-1s site has a plateau checker that compares your rate of loss with the trial curves once you have enough weeks to compare.

After week 12

The label ladders continue: Wegovy to 1.7 mg at week 13 and 2.4 mg at week 17; Zepbound to 10 mg at week 13, 12.5 at 17 and 15 at 21, with maintenance allowed at 5, 10 or 15 mg (section 2.1). Ozempic's optional steps stop at 2 mg. The week-by-week planner will give you the dates to week 20. The molecule-specific hubs take it from there: Semaglutide Hub and Tirzepatide Hub, and FormBlends' own tirzepatide introduction for the longer view.

Checklist for the end of week 12

• Three-month review booked or done; blood pressure and pulse recorded.
• Labs repeated if your prescriber wanted them.
• Twelve lines in the log; you can see your own pattern around step-ups.
• You know your target maintenance dose and the date of each remaining step.
• You have read the myths page before anyone else tells you what to expect.